

Applicants: Peter S. Linsley et al.
Serial No.: 722,101
Filed: June 27, 1991
Page 2

Please amend the subject application as follows:

In the Claims:

Please cancel claims 2, 16, 43-46, 50 and 58.

Please amend claims 1, 3, 18, 21, 35, 47, 51, and 52 as follows.

B1
sub C1
--1. (amended)

A method for regulating functional T cell responses comprising contacting CD28 positive T cells with [a ligand for CD28 receptor] the B7 antigen thereby regulating functional T cell responses.--

B2
sub C2
--3. (amended)

The method of claim [2]1, wherein [said] the CD28 positive T cells are contacted with a fragment or derivative of [said] the B7 antigen.--

B3
sub C3
--18. (amended)

The method of claim 1, wherein [said] the CD28 positive T cells are reacted with the [ligand] B7 antigen in soluble form and [said] the T cell responses are inhibited.--

B4
sub C4
--15. (amended)

The method of claim 1 further comprising adding anti-CD2 or anti-CD3 antibody to co-react with said T cells.

B5
sub C5
--21. (amended)

The method of claim 19, wherein [said] the ligand is a Fab fragment of a monoclonal antibody reactive with B7 antigen[.] and [said] the T cell responses are inhibited.--

B6
Sub C8
--35. (amended)

A method for [inhibiting functional T cell responses] preventing the binding of the CD28 receptor to the B7 antigen so as to inhibit functional T cell responses comprising contacting CD28 positive T cells with an anti-CD28 monoclonal antibody which recognizes and binds to [ligand reactive with] the CD28 receptor so as to prevent binding of [said] the receptor to the B7 antigen.--

B7
Sub C10
--47. (amended)

The method of claim [45] 77, wherein said ligand contains a portion of the extracellular domain of the B7 antigen.--

--51. (amended)

The method of claim [45] 77, wherein [said] the cytokine[s are] is selected from the group consisting of interleukins, interferons, transforming growth factors, tumor necrosis factor and colony stimulating factors.--

B8
Sub C12
--52. (amended)

A method for treating a subject with an immune system disease[s] mediated by CD28 positive T cell interactions with B7 positive cells comprising administering to [a] the subject a ligand for CD28 receptor to regulate the functional T cell response [and/or to regulate cytokine levels] and a pharmaceutically acceptable carrier.--

Please add new claim 77 as follows:

B9
Sub C15
--77. (new)

A method for regulating the level of a cytokine in vivo comprising administering to a subject a ligand